Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy. Recent large randomized clinical studies - AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides) and HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) - delivered some disappointing results, leading to the conclusion that no further benefit (decreased parameters of cardiovascular risk) is achieved by adding niacin to existing statin therapy in patients with high cardiovascular risk. Moreover, in these studies, several adverse effects of the treatment were observed; therefore, niacin treatment for hypolipidemias is not recommended. In this paper, we analyze the mechanisms underlying the hypolipidemic and antiatherogenic effects of niacin as well as some limitations of the designs of the AIM HIGH and HP2-THRIVE studies. We also provide the possibilities of rational usage of niacin for specific types of dyslipidemias.

4th Department of Medicine 1st Faculty of Medicine Charles University Prague Prague Czech Republic

4th Dept Internal Med 1st Fac Med Charles Univ Prague Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Research and Development Center C2P s r o Chlumec nad Cidlinou Czech Republic

Zobrazit více v PubMed

Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61. PubMed PMC

Taylor AJ, Sullenberger LE, Lee HJ, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–17. PubMed

Gotto AM, Pownall H. Manual of Lipid Disorders. 3rd ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2003.

Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. PubMed

Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25. PubMed

Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. 2012;8:517–28. PubMed

Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81. [No authors listed] PubMed

Carlson LA, Danielson M, Ekberg I, et al. Atherosclerosis. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977;28:81–86. PubMed

Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55. PubMed

Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–40. PubMed

Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–89. PubMed

Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22. PubMed

Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95–104. PubMed

Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. PubMed

HPS2-THRIVE Collaborative Group. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12. PubMed

Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6 Suppl 1):S22–31. PubMed

Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A) Cell Death Differ. 2008;15:134–42. PubMed

Martin PM, Ananth S, Cresci G, et al. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol Vis. 2009;15:362–72. PubMed PMC

Viljoen A, Wierzbicki AS. Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug Health Patient Saf. 2010;2:61–71. PubMed PMC

Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32:582–88. PubMed PMC

Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625–30. PubMed

Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes. 2010;1:116–28. PubMed PMC

Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol. 2011;9:385–400. PubMed

Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61:440–46. PubMed

Nicholls SJ. Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve Clin J Med. 2012;79:38–43. PubMed

Blomgarden Z, Handelsman Y. Did AIM-HIGH aim too low? J Diabetes. 2012;4:1–2. PubMed

Cannon CP on behalf of the IMPROVE IT Investigators. IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes AHA Scientific Sessions 2014 Chicago, American Heart Association Scientific Sessions 2014 Chicago; United States of America, Chicago. 15–19 November.

Al-Hijji M, Martin SS, Joshi PH, Jones SR. Effect of equivalent on-treatment apolipoprotein levels on outcomes (from the AIM-HIGH and HPS2-THRIVE) Am J Cardiol. 2013;112:1697–700. PubMed

van den Oever IA, Nurmohamed MT, Lems WF. Niacin for reduction of cardiovascular risk. N Engl J Med. 2014;371:1942. PubMed

Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617–70. PubMed PMC

Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813–19. PubMed

Gaidarov I, Chen X, Anthony T, et al. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell Signal. 2013;25:2003–16. PubMed

Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of imunity. Trends Immunol. 2002;23:144–50. PubMed

Harizi H. The immunobiology of prostanoid receptor signaling in connecting innate and adaptive immunity. Biomed Res Int. 2013;2013:683405. PubMed PMC

Yang YL, Hu M, Chang M, Tomlinson B. A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. J Clin Pharm Ther. 2013;38:528–32. PubMed

Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, D.C.: National Academy Press; 1998. pp. 123–49. PubMed

Shils ME, Shike M, editors. Modern nutrition in health and disease. 10th ed. Lippincott Williams & Wilkins; 2006.

Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the third national health and nutrition examination survey. Diabetes. 2003;52:2346–52. PubMed

Shen J, Lai CQ, Mattei J, et al. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: The Boston Puerto Rican Health Study. Am J Clin Nutr. 2010;91:337–42. PubMed PMC

Bian S, Gao Y, Zhang M, et al. Dietary nutrient intake and metabolic syndrome risk in Chinese adults: a case-control study. Nutr J. 2013;12:106. PubMed PMC

Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003;77:1352–60. PubMed

Babaei-Jadidi R, Karachalias N, Kupich C, et al. High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia. 2004;47:2235–46. PubMed

Zhao M, Lamers Y, Ralat MA, et al. Marginal vitamin B-6 deficiency decreases plasma (n−3) and (n−6) PUFA concentrations in healthy men and women. J Nutr. 2012;142:1791–97. PubMed PMC

Zhao M, Ralat MA, da Silva V, et al. Vitamin B-6 restriction impairs fatty acid synthesis in cultured human hepatoma (HepG2) cells. Am J Physiol Endocrinol Metab. 2013;304(4):E342–51. PubMed PMC

Heemskerk MM, Dharuri HK, van den Berg SA, et al. Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile. J Lipid Res. 2014;55:2532–40. PubMed PMC

Ridker PM, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. PubMed

Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. PubMed

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37:2225–32. PubMed